What is Scailyte?
Scailyte AG, an innovative spin-off from ETH Zurich, operates at the intersection of single-cell biology and artificial intelligence. The company's core asset, the ScaiVision platform, utilizes advanced machine learning to process complex, multimodal single-cell datasets, including RNA, TCR, and BCR sequencing. By associating these high-resolution biological data points with clinical endpoints, Scailyte identifies ultra-sensitive biomarkers that are critical for disease diagnosis, progression monitoring, and predicting therapy response.
The firm's market position is defined by its ability to bridge the gap between raw biological data and actionable clinical insights. By focusing on high-unmet-need indications in oncology and immunology, Scailyte provides pharmaceutical and biotech companies with the tools necessary to develop next-generation companion diagnostics (CDx) and in-vitro diagnostic (IVD) assays. This data-centric approach ensures that therapeutic interventions are more precise, ultimately improving patient outcomes through personalized medicine.
How much funding has Scailyte raised?
Scailyte has raised a total of $2.9M across 1 funding round:
Angel/Seed
$2.9M
Angel/Seed (2018): $2.9M with participation from Swisscom Ventures
Key Investors in Scailyte
Swisscom Ventures
The venture capital arm of the Swiss telecommunications leader, focusing on early-stage and growth-stage investments in digital transformation and deep-tech sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Scailyte?
With the recent infusion of capital, Scailyte is strategically positioned to expand its global clinical network and enhance the predictive power of the ScaiVision platform. The company's roadmap focuses on translating its biomarker signatures into commercial-grade diagnostic products, a move that will likely involve deeper integration with large-scale pharmaceutical pipelines. As the biotech industry increasingly shifts toward precision-based treatment models, Scailyte's ability to provide high-fidelity diagnostic data makes it an essential partner for drug developers. Future growth will likely be driven by the commercialization of its IVD assays and the continued refinement of its AI-driven biomarker discovery engine, ensuring the company remains at the vanguard of the diagnostic revolution.
See full Scailyte company page
